| HER3 signaling and targeted therapy in cancer R Mishra, H Patel, S Alanazi, L Yuan, JT Garrett Oncology reviews 12 (1), 2018 | 195 | 2018 |
| Current advances in the treatment of BRAF-mutant melanoma H Patel, N Yacoub, R Mishra, A White, L Yuan, S Alanazi, JT Garrett Cancers 12 (2), 482, 2020 | 149 | 2020 |
| Activating HER3 mutations in breast cancer R Mishra, S Alanazi, L Yuan, T Solomon, TM Thaker, N Jura, JT Garrett Oncotarget 9 (45), 27773, 2018 | 30 | 2018 |
| BRAF mutant melanoma adjusts to BRAF/MEK inhibitors via dependence on increased antioxidant SOD2 and increased reactive oxygen species levels L Yuan, R Mishra, H Patel, S Alanazi, X Wei, Z Ma, JT Garrett Cancers 12 (6), 1661, 2020 | 28 | 2020 |
| Utilization of reactive oxygen species targeted therapy to prolong the efficacy of BRAF inhibitors in melanoma L Yuan, R Mishra, H Patel, S Abdulsalam, KD Greis, AL Kadekaro, ... Journal of Cancer 9 (24), 4665, 2018 | 25 | 2018 |
| An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice WC Chou, Q Chen, L Yuan, YH Cheng, C He, NA Monteiro-Riviere, ... Journal of Controlled Release 361, 53-63, 2023 | 14 | 2023 |
| Phosphoinositide 3-Kinase (PI3K) reactive oxygen species (ROS)-activated prodrug in combination with anthracycline impairs pi3k signaling, increases DNA damage response and … R Mishra, L Yuan, H Patel, AS Karve, H Zhu, A White, S Alanazi, P Desai, ... International Journal of Molecular Sciences 22 (4), 2088, 2021 | 13 | 2021 |
| Oxidative Cyclization‐Induced Activation of a Phosphoinositide 3‐Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics H Zhu, R Mishra, L Yuan, SF Abdul Salam, J Liu, G Gray, AD Sterling, ... ChemMedChem 14 (22), 1933-1939, 2019 | 9 | 2019 |
| A web-based interactive physiologically based pharmacokinetic (iPBPK) model for meloxicam in broiler chickens and laying hens L Yuan, WC Chou, ED Richards, LA Tell, RE Baynes, JL Davis, JE Riviere, ... Food and Chemical Toxicology 168, 113332, 2022 | 8 | 2022 |
| Pharmacokinetics and tumor delivery of nanoparticles L Yuan, Q Chen, JE Riviere, Z Lin Journal of Drug Delivery Science and Technology, 104404, 2023 | 7 | 2023 |
| Role of reactive oxygen species and targeted therapy in metastatic melanoma R Mishra, H Patel, L Yuan, J Garrett Cancer Research Frontiers 4 (1), 101-130, 2018 | 7 | 2018 |
| HER3 signaling and targeted therapy in cancer. Oncol Rev. 2018; 12 (1): 355 R Mishra, H Patel, S Alanazi, L Yuan, JT Garrett Epub 2018/07/31. https://doi. org/10.4081/oncol. 2018.355 PMID: 30057690, 0 | 5 | |
| Residue depletion profiles and withdrawal interval estimations of meloxicam in eggs and ovarian follicles following intravenous (Meloxicam solution for injection) and oral … L Yuan, Z Lin, RS Dutch, ED Richards, MO Clapham, N Burmas, ... Regulatory Toxicology and Pharmacology 132, 105170, 2022 | 4 | 2022 |
| Meta-Analysis of Nanoparticle Distribution in Tumors and Major Organs in Tumor-Bearing Mice Q Chen, L Yuan, WC Chou, YH Cheng, C He, NA Monteiro-Riviere, ... ACS nano 17 (20), 19810-19831, 2023 | 3 | 2023 |
| Role of HER3 signaling pathways in ER+ and HER2+ breast cancers R Mishra, S Alanazi, H Patel, L Yuan, JT Garrett Cancer Research 79 (13_Supplement), 389-389, 2019 | 2 | 2019 |
| HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers SM Alanazi, W Feroz, R Mishra, MK Kilroy, H Patel, L Yuan, SJ Storr, ... Plos one 18 (5), e0285251, 2023 | 1 | 2023 |
| Abstract P4-21-22: Oncogenic potential of ERBB3 mutations in human mammary epithelial cells R Mishra, L Yuan, T Solomon, JT Garrett Cancer Research 77 (4_Supplement), P4-21-22-P4-21-22, 2017 | 1 | 2017 |
| Tumor targeting HPMA-porphyrin-99mTc copolymer molecular imaging agent L Yuan, Y Ma, J Yuan Journal of Biomaterials Science, Polymer Edition 25 (18), 2066-2079, 2014 | 1 | 2014 |
| Role of Reactive Oxygen Species and Therapeutic Implications in BRAF Mutant Melanoma L Yuan University of Cincinnati, 2020 | | 2020 |
Rosalin MishraResearch Associate, University of CincinnatiVerified email at ucmail.uc.edu
